Key result
Transcatheter aortic valve implantation in high-risk elderly patients with severe symptomatic aortic stenosis resulted in a 12-month all-cause mortality rate of 17.8%.
Observational (n=101)
No
Answers are grounded in this paper and cite their sources.
TAVI is an effective treatment option for elderly, high-risk patients with severe symptomatic aortic stenosis, demonstrating an acceptable 12-month mortality rate of 17.8% and significant symptom alleviation.
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) is a less invasive treatment option for elderly, high-risk patients with symptomatic severe aortic stenosis (AS) than aortic valve replacement. More importantly, TAVI improves survival and quality of life as compared to medical treatment in inoperable patients. AIM: To assess early- and mid-term clinical outcomes after TAVI. MATERIAL AND METHODS: All consecutive high-risk patients with severe symptomatic AS undergoing TAVI from November 2008 to August 2014 were enrolled. The clinical and procedural characteristics, as well as clinical outcomes including mortality during 12-month follow-up, were assessed. RESULTS: A total of 101 consecutive patients underwent TAVI for native aortic valve stenosis (100%). Patients were elderly, with a median age of 81.0 (76.0-84.0) years, 60.4% were female and 83.2% presented with NYHA III/IV. Median baseline EuroSCORE I and STS scores were 14.0 (10.0-22.5)% and 12.0 (5.0-24.0)%, respectively. The main periprocedural and in-hospital complications were minor vascular complications, bleeding requiring blood transfusions, and the need for a permanent pacemaker. In-hospital, 30-day, 6-month and 12-month mortality rates were 6.9%, 10.9%, 15.8% and 17.8%, respectively. CONCLUSIONS: A mortality rate of < 20% after 12 months seems acceptable given the high-risk population enrolled.
No takes yet. Share an insight, caveat, or question.
Bagieński et al. (2016) conducted an observational in Severe symptomatic aortic stenosis (n=101). Transcatheter aortic valve implantation (TAVI) was evaluated on All-cause mortality at 12 months. Transcatheter aortic valve implantation in high-risk elderly patients with severe symptomatic aortic stenosis resulted in a 12-month all-cause mortality rate of 17.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: